Tenon Medical (NASDAQ:TNON) Issues Earnings Results

Tenon Medical (NASDAQ:TNON) posted its quarterly earnings data on Thursday. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.14, FiscalAI reports. The firm had revenue of $1.48 million for the quarter, compared to analyst estimates of $1.38 million. Tenon Medical had a negative return on equity of 365.39% and a negative net margin of 318.36%.

Here are the key takeaways from Tenon Medical’s conference call:

• Tenon reported record full-year revenue of $3.9 million (up 20% YoY) and Q4 revenue of $1.5 million (up 92% YoY), driven by increased surgical volume and new physician adoption.
• Gross margins improved materially—Q4 gross profit was $1.0 million (69% margin) vs. 46% a year earlier, and full-year gross margin rose to 60%—attributed to higher revenue and better absorption of fixed costs.
• The company received FDA 510(k) clearance for the SImmetry+ SI joint fusion system and completed early clinical cases, supporting its commercial rollout and broader multi‑product positioning.
• Tenon raised financing to bolster its balance sheet—a $2.85M at‑the‑market PIPE in the quarter and a subsequent $4.3M private placement of senior convertible notes—providing runway for commercial expansion but introducing potential capital structure considerations.
• Management highlighted improved operational discipline and a lower run rate for operating expenses (Q4 operating expense of $3.9M called out as a new baseline), which, together with revenue gains, narrowed net losses year‑over‑year.

Tenon Medical Trading Down 3.9%

TNON opened at $0.80 on Friday. The company has a market cap of $8.92 million, a P/E ratio of -0.40 and a beta of 1.25. The company’s 50 day moving average is $0.84 and its 200-day moving average is $1.04. Tenon Medical has a 1-year low of $0.64 and a 1-year high of $5.85.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tenon Medical in a research note on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Tenon Medical currently has a consensus rating of “Hold” and a consensus target price of $3.00.

Hedge Funds Weigh In On Tenon Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in TNON. Jane Street Group LLC acquired a new stake in Tenon Medical in the first quarter valued at approximately $29,000. Geode Capital Management LLC increased its holdings in shares of Tenon Medical by 34.6% during the fourth quarter. Geode Capital Management LLC now owns 66,640 shares of the company’s stock worth $63,000 after buying an additional 17,137 shares in the last quarter. Finally, DRW Securities LLC acquired a new position in shares of Tenon Medical during the fourth quarter worth $98,000. Institutional investors own 22.74% of the company’s stock.

About Tenon Medical

Tenon Medical, Inc is a development-stage medical device company focused on the research, development and commercialization of next-generation surgical biologic adhesives and sealants. The company’s proprietary platform is designed to create tissue-compatible adhesives that can serve as alternatives or complements to traditional sutures and staples, with the goal of improving surgical efficiency, reducing postoperative complications and enhancing patient outcomes.

Tenon Medical’s product pipeline centers on protein-based polymer formulations that cross-link in situ to form a flexible, yet durable, bond with native tissue.